MARLBOROUGH, Mass.--(BUSINESS WIRE)--Cytyc Corporation (Nasdaq: CYTC) today announced that a total of eight studies evaluating performance of the NovaSure® System for endometrial ablation were presented at the 33rd Annual Meeting of the American Association of Gynecologic Laparoscopists (AAGL) in Las Vegas. The studies covered a range of performance characteristics and patient populations. The studies included two evaluating the use of the NovaSure System in an in-office setting, and one presenting five-year follow-up data on the efficacy of the NovaSure System for the treatment of abnormal uterine bleeding using second generation endometrial ablation.
